SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-022241
Filing Date
2023-05-15
Accepted
2023-05-15 16:27:21
Documents
77
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q qncx-20230331.htm   iXBRL 10-Q 3124042
2 EX-10.1 qncx-ex10_1.htm EX-10.1 601690
3 EX-31.1 qncx-ex31_1.htm EX-31.1 17401
4 EX-31.2 qncx-ex31_2.htm EX-31.2 17365
5 EX-32.1 qncx-ex32_1.htm EX-32.1 13201
6 EX-32.2 qncx-ex32_2.htm EX-32.2 13204
  Complete submission text file 0000950170-23-022241.txt   12741561

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20230331_lab.xml EX-101.LAB 502320
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20230331_pre.xml EX-101.PRE 381032
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT qncx-20230331_cal.xml EX-101.CAL 53221
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT qncx-20230331_def.xml EX-101.DEF 234630
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20230331.xsd EX-101.SCH 58609
71 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20230331_htm.xml XML 2794011
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38890 | Film No.: 23923017
SIC: 2836 Biological Products, (No Diagnostic Substances)